ADARx is focused on the development of next-generation RNA therapeutics. Credit: MattL_Images / Shutterstock.com.

ADARx Pharmaceuticals has concluded an oversubscribed Series C financing, securing $200m for advancing its clinical programmes, including ADX-324 and ADX-038.

Led jointly by TCGX and Bain Capital Life Sciences, the financing round witnessed participation from new investors such as Commodore Capital, Cormorant Asset Management, Invus, Marshall Wace, Redmile Group, HBM Healthcare Investments and BlackRock.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It also involved existing investors SR One Capital Management, OrbiMed, Lilly Asia Ventures and Ascenta Capital.

ADX-324 offers a new method to treat hereditary angioedema, a genetic disease characterised by painful, rapid and potentially life-threatening episodes of swelling.

The company is developing ADX-038 to treat multiple complement-mediated diseases.

See Also:

It will also use the funding to support the development of a pipeline of mRNA silencing or editing candidates to treat several diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ADARx Pharmaceuticals president and CEO Dr Zhen Li stated: “The early Phase I clinical data strongly support the potential of ADX-324 to be the best-in-class treatment for patients suffering from hereditary angioedema.

“Moreover, the clinical data validate our proprietary targeted delivery PLR platform and our broad SPE technology. With this financing, we are well-positioned to achieve our clinical milestones for multiple clinical programmes and to build a leading company in RNA therapeutics.”

Bain Capital Life Sciences partner Dr Ricky Sun and TCGX managing partner Dr Chen Yu will become members of the ADARx board of directors.

The company has a pipeline of RNA therapeutics to treat diseases across a range of therapeutic areas.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.